- BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
May 13, 2026 · businesswire.com
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton's tyrosine ki.
- BEONE MEDICINES' BEQALZI™ (SONROTOCLAX) APPROVED BY U.S. FDA AS FIRST AND ONLY BCL2 INHIBITOR FOR R/R MANTLE CELL LYMPHOMA
May 13, 2026
SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (“BEONE”) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ACCELERATED APPROVAL TO BEQALZI™ (BEE-KAHL-ZEE; SONROTOCLAX), A FOUNDATIONAL, NEXT-GENERATION BCL2 INHIBITOR, FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL), AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BRUTON'S TYROSINE KI.
- BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
May 6, 2026 · seekingalpha.com
BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
- BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
May 6, 2026 · businesswire.com
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne's continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapid.
- BEONE MEDICINES ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES
May 6, 2026
SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS AND CORPORATE UPDATES FROM THE FIRST QUARTER OF 2026. JOHN V. OYLER, CO-FOUNDER, CHAIRMAN, AND CEO, BEONE, SAID: “THESE STRONG FIRST-QUARTER RESULTS REINFORCE BEONE'S CONTINUED GROWTH AS A GLOBAL ONCOLOGY LEADER, DRIVEN BY DISCIPLINED COMMERCIAL EXECUTION, AND UNDERPINNED BY OUR ESTABLISHED HEMATOLOGY LEADERSHIP, AND AN IMPRESSIVE, RAPID.
- Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, Internatioinal Paper, Trade Desk, and More
May 4, 2026 · 247wallst.com
Pre-Market Stock Futures: Futures are trading lower as we start off the new week, as oil surges higher amid reports that a U.S. warship was turned back in the Strait of Hormuz, but what a start we had to the new month on Friday. The Thursday close on April's last trading day marked the best... Here Are Monday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, Internatioinal Paper, Trade Desk, and More
- U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA
Apr 29, 2026 · businesswire.com
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or eso.
- U.S. FDA GRANTS PRIORITY REVIEW TO BEONE MEDICINES' TEVIMBRA IN FIRST-LINE HER2+ GEA
Apr 29, 2026
SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED PRIORITY REVIEW TO A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR TEVIMBRA® (TISLELIZUMAB) IN COMBINATION WITH ZIIHERA® (ZANIDATAMAB) AND CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED/METASTATIC HER2-POSITIVE (HER2) GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESO.
- BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
Apr 22, 2026 · businesswire.com
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a time.
- BEONE MEDICINES TO ANNOUNCE FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 6
Apr 22, 2026
SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, MAY 6, 2026 BEFORE THE FINANCIAL MARKETS OPEN. FOLLOWING THE RELEASE OF THE FINANCIALS, THE COMPANY WILL HOST A LIVE WEBCAST WITH MANAGEMENT AT 8:00 A.M. ET. THE LIVE WEBCAST OF THIS EVENT CAN BE ACCESSED FROM THE INVESTORS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.BEONEMEDICINES.COM.TO ENSURE A TIME.